Syfovre (pegcetacoplan (intravitreal))
An approved treatment for Geographic Atrophy.
Drug facts
The same compound appears under different names depending on the context. Here is how to identify Pegcetacoplan (intravitreal) wherever you encounter it, plus the key facts at a glance.
- Generic name
- Pegcetacoplan (intravitreal)
- Brand name
- Syfovre
- Development code
- APL-2
- Drug class
- Complement C3 inhibitor (intravitreal)
- Manufacturer
- Apellis Pharmaceuticals (part of Biogen since May 2026)
- How it's taken
- Injection into the eye every 25 to 60 days
An eye injection that slows the growth of geographic atrophy (GA), the advanced form of dry age-related macular degeneration (AMD).
- The FDA approved Syfovre on February 17, 2023[2]. It is given into each affected eye once every 25 to 60 days[1].
- In 2 trials lasting 24 months, GA lesions grew 17.4-21.9% less than with sham (mock) injections, depending on the trial and dosing schedule[1].
- Syfovre contains the same molecule as Empaveli, which is infused under the skin for blood and kidney diseases, but it is a separate product with its own label, a much smaller dose and different risks.
We'll email you when Syfovre's FDA label changes, when the FDA acts on it, and when new trials for Geographic Atrophy open. Unsubscribe anytime.
- Trial Alerts, when a new trial opens or a trial changes
- Disease Updates, FDA decisions and condition news, usually 1 or 2 emails a month
We never share your email. Unsubscribe anytime. Privacy policy · Check any health site
Where Pegcetacoplan (intravitreal) fits
Syfovre (pegcetacoplan) is 1 of 2 FDA-approved treatments for geographic atrophy secondary to age-related macular degeneration, both complement inhibitors injected into the eye to slow lesion growth.
- Syfovre was approved for geographic atrophy on February 17, 2023[3].
- Izervay (avacincaptad pegol), approved on August 4, 2023, blocks complement protein C5 and is given once a month, while Syfovre blocks C3 and is given every 25 to 60 days[7][1].
- Syfovre and Izervay have not been compared head to head, and each label measured lesion growth against sham injections, not vision[1][7].
- Wet AMD is a warning on both labels, and retinal vasculitis is a warning on the Syfovre label[1][7].
- Anyone weighing a geographic atrophy treatment can ask their retina specialist how often injections would be needed and which changes in vision should be reported right away.
How Pegcetacoplan (intravitreal) works
The macula is the small center of the retina that gives sharp, straight-ahead vision. In geographic atrophy (GA), patches of light-sensing cells and the support layer beneath them die off and slowly spread. The Syfovre trials measured how fast those patches grew[1]. Complement, a set of immune proteins, is thought to take part in that damage[9].
Pegcetacoplan binds complement protein C3 and its fragment C3b, which the label says controls the splitting of C3 and the production of the complement signals further down the chain[1]. C3 acts earlier in the complement chain than C5, the protein that Izervay (avacincaptad pegol) blocks[6][7].
Syfovre slows how fast lesions grow. The label's trial results measure lesion growth, and it reports no vision results, so Syfovre is not described as restoring vision already lost[1].
Syfovre and Empaveli contain the same molecule, pegcetacoplan. Syfovre puts 15mg into the eye every 25 to 60 days, and the label says the amount that reaches the rest of the body is low[1]. Empaveli is infused under the skin twice a week, 1,080mg for adults, for paroxysmal nocturnal hemoglobinuria (PNH) and, from age 12, C3 glomerulopathy and primary IC-MPGN, and its label carries a boxed warning for serious infections, required vaccines and a restricted safety program (REMS)[6]. The Syfovre label has no boxed warning, no vaccine requirement and no REMS[1].
Side effects and safety
- Retinal vasculitis and retinal vascular occlusion. Inflammation or blockage of the retina's blood vessels, usually with inflammation inside the eye, has been reported after approval. It can happen with the first dose and can cause severe vision loss. Syfovre is stopped in anyone who develops it, and the label says any change in vision should be reported without delay.
- Wet AMD (neovascular AMD). By month 24, developed in 12% of people given Syfovre monthly, 7% every other month and 3% given sham. Any anti-VEGF treatment needed for wet AMD is given separately from Syfovre.
- Endophthalmitis and retinal detachment. Eye injections can cause a serious infection inside the eye or a detached retina. Report eye pain, redness, light sensitivity or blurred vision without delay.
- Inflammation inside the eye. Episodes such as uveitis, vitritis and iritis occurred in the trials. Treatment can resume after the inflammation clears.
- Raised eye pressure. Eye pressure can rise within minutes of the injection, so it is checked before, and blood flow to the optic nerve after, each injection.
- Allergic reactions. Anaphylaxis, rash and hives have been reported after approval; a known allergy to pegcetacoplan or its ingredients rules Syfovre out.
- Eye pressure checked before each injection
- Eye pressure and optic nerve blood flow checked right after each injection
- Regular eye exams for signs of wet AMD
- Report any change in vision, eye pain or redness without delay
Syfovre has no boxed warning[1]. It must not be used when there is an infection in or around the eye, active inflammation inside the eye, or an allergy to pegcetacoplan or its ingredients; whole-body allergic reactions, including anaphylaxis, rash and hives, have been reported[1].
The label warns about retinal vasculitis (inflammation of the blood vessels of the retina) and retinal vascular occlusion (a blocked retinal blood vessel), usually alongside inflammation inside the eye, which can happen with the first dose and can cause severe vision loss; Syfovre is stopped in anyone who develops them, and any change in vision should be reported without delay[1].
By month 24 of the trials, wet AMD (neovascular AMD, where abnormal new blood vessels grow under the retina) developed in 12% of people given Syfovre monthly, 7% given it every other month and 3% given sham[1]. Other warnings are endophthalmitis (a serious infection inside the eye) and retinal detachment, which can follow any eye injection, inflammation inside the eye, and a rise in eye pressure within minutes of the injection[1].
Through month 24, the most common side effects in the treated eye, for monthly, every-other-month and sham groups, were eye discomfort (13%, 10% and 11%), wet AMD (12%, 7% and 3%), floaters (10%, 7% and 1%) and bleeding on the white of the eye (8%, 8% and 4%)[1]. Optic ischemic neuropathy, loss of blood flow to the optic nerve, was reported in 1.7% of people treated monthly, 0.2% treated every other month and 0.0% given sham[1].
Deaths occurred in 6.7%, 3.6% and 3.8% of those groups, and the label says the rates and causes were consistent with an elderly population[1].
This is not a complete list of side effects. Talk to your doctor or pharmacist about what to expect and when to seek medical attention.
Taking Pegcetacoplan (intravitreal)
Each dose is 15mg (0.1mL of a 150mg/mL solution) injected into the vitreous, the clear gel inside the eye, by a qualified physician, once every 25 to 60 days in each affected eye[1]. The injection is done under sterile conditions after numbing and an antiseptic, with a separate vial for each eye. Eye pressure is checked before the injection, and eye pressure and optic nerve blood flow are checked right after it[1].
In the trials, people were treated either monthly or every other month[1]. The label gives no age-based dose change; about 97% of people treated in the trials were 65 or older and about 72% were 75 or older[1]. Safety and effectiveness in children have not been established. For pregnancy, the label says there are no adequate studies and that use may be considered after weighing risks and benefits, since little of the drug reaches the rest of the body after an eye injection[1].
Availability and cost
Only available as the brand-name product.
Help paying for Syfovre
With private insurance, the drugmaker's copay card can lower what you pay for Syfovre. Drugmaker copay cards can't be used with Medicare, Medicaid or TRICARE. Pick your insurance below to see which offers fit you.
- Copay help
SYFOVRE Co-pay Program: for eligible patients enrolled in ApellisAssist who are not covered under government insurance programs such as Medicare, Medicaid, VA/DoD or TRICARE. The page does not list dollar amounts or an annual maximum. Apellis reserves the right to modify or end the program at any time.
For: private insurance · source - Insurance and case manager help
A dedicated Apellis Care Educator (ACE) gives insurance support during treatment and helps eligible patients with financial assistance and enrolling in affordability programs. ACEs do not give medical advice. Call 1-888-APELLIS (1-888-273-5547), Monday to Friday, 8 AM to 8 PM ET.
The official page does not say who qualifies. Ask the program. · source
Good to know: Terms read on syfovre.com/resources-for-you/apellisassist on November 14, 2026; the site footer now reads ©2026 Biogen. The page names no free-drug program and gives no copay amounts or cap. Third-party listings describe a $25,000 yearly copay cap and a free-drug program for uninsured or underinsured patients, but Apellis's own page does not, so neither is recorded. The syfovre.com home page links to no cost or savings page.
Access and eligibility
Approved for geographic atrophy secondary to age-related macular degeneration, in each affected eye. Not used when there is an infection in or around the eye, active inflammation inside the eye or an allergy to pegcetacoplan or its ingredients. Safety and effectiveness in children have not been established, and the trials enrolled people aged 60 to 100.
Source: ApellisAssist (Apellis, a Biogen company)
Access program details are provided for informational purposes and may vary based on insurance coverage, geographic location, and individual circumstances. Confirm current eligibility directly with the manufacturer or your specialty pharmacy.
Clinical trial results
Approval rested on 2 sham-controlled trials, OAKS (NCT03525613) and DERBY (NCT03525600), which together randomized 1,258 people with GA from AMD: 839 to Syfovre given monthly or every other month and 419 to sham, all treated for 24 months. Ages ranged from 60 to 100, with an average of 78.7[1][4][5]. Lesion growth was measured with fundus autofluorescence, an imaging scan of the back of the eye.
Over 24 months in OAKS, the label's modeled lesion growth was 3.11mm² on monthly Syfovre and 3.26mm² every other month, against 3.98mm² on sham, 21.9% and 18.1% less[1]. In DERBY it was 3.28mm² and 3.31mm² against 4.00mm², 18.1% and 17.4% less[1]. In DERBY the difference in the first 6 months was small (5.7% and 8.2%), and its confidence interval included no difference, while from month 18 to 24 lesions grew 36.1% and 29.1% less than with sham[1].
Before month 24, 21-31% of people in each group stopped treatment[1]. The main goal in both trials was slower lesion growth, not better vision.
Development history
Apellis Pharmaceuticals developed pegcetacoplan as APL-2, and the FDA first approved it as Empaveli, an infusion under the skin for PNH, on May 14, 2021[6]. Syfovre, the eye injection, was approved on February 17, 2023 for GA secondary to AMD, under its own application (NDA 217171) as a new dosage form with priority review[2][3].
The FDA approved labeling supplements on November 30, 2023 and December 20, 2024[2], and the current label, revised in July 2025, lists the retinal vasculitis and retinal vascular occlusion warning, a contraindication for allergic reactions added in December 2024, and post-approval reports of retinal vasculitis and of anaphylaxis, rash and hives[1].
Biogen completed its acquisition of Apellis on May 14, 2026, and Apellis is now a wholly owned subsidiary of Biogen[10]. Izervay (avacincaptad pegol), a C5 inhibitor from Astellas, was approved for the same use on August 4, 2023[8].
Explore Geographic Atrophy trials
Other Geographic Atrophy treatments
Common questions about Pegcetacoplan (intravitreal)
▸What is Pegcetacoplan (intravitreal) (Syfovre)?
An eye injection that slows the growth of geographic atrophy (GA), the advanced form of dry age-related macular degeneration (AMD). The FDA approved Syfovre on February 17, 2023[2]. It is given into each affected eye once every 25 to 60 days[1]. In 2 trials lasting 24 months, GA lesions grew 17.4-21.9% less than with sham (mock) injections, depending on the trial and dosing schedule[1]. Syfovre contains the same molecule as Empaveli, which is infused under the skin for blood and kidney diseases, but it is a separate product with its own label, a much smaller dose and different risks.
▸How does Pegcetacoplan (intravitreal) work?
The macula is the small center of the retina that gives sharp, straight-ahead vision. In geographic atrophy (GA), patches of light-sensing cells and the support layer beneath them die off and slowly spread. The Syfovre trials measured how fast those patches grew[1]. Complement, a set of immune proteins, is thought to take part in that damage[9].
Pegcetacoplan binds complement protein C3 and its fragment C3b, which the label says controls the splitting of C3 and the production of the complement signals further down the chain[1]. C3 acts earlier in the complement chain than C5, the protein that Izervay (avacincaptad pegol) blocks[6][7].
Syfovre slows how fast lesions grow. The label's trial results measure lesion growth, and it reports no vision results, so Syfovre is not described as restoring vision already lost[1].
Syfovre and Empaveli contain the same molecule, pegcetacoplan. Syfovre puts 15mg into the eye every 25 to 60 days, and the label says the amount that reaches the rest of the body is low[1]. Empaveli is infused under the skin twice a week, 1,080mg for adults, for paroxysmal nocturnal hemoglobinuria (PNH) and, from age 12, C3 glomerulopathy and primary IC-MPGN, and its label carries a boxed warning for serious infections, required vaccines and a restricted safety program (REMS)[6]. The Syfovre label has no boxed warning, no vaccine requirement and no REMS[1].
▸What are the side effects of Pegcetacoplan (intravitreal)?
Syfovre has no boxed warning[1]. It must not be used when there is an infection in or around the eye, active inflammation inside the eye, or an allergy to pegcetacoplan or its ingredients; whole-body allergic reactions, including anaphylaxis, rash and hives, have been reported[1]. The label warns about retinal vasculitis (inflammation of the blood vessels of the retina) and retinal vascular occlusion (a blocked retinal blood vessel), usually alongside inflammation inside the eye, which can happen with the first dose and can cause severe vision loss; Syfovre is stopped in anyone who develops them, and any change in vision should be reported without delay[1]. By month 24 of the trials, wet AMD (neovascular AMD, where abnormal new blood vessels grow under the retina) developed in 12% of people given Syfovre monthly, 7% given it every other month and 3% given sham[1]. Other warnings are endophthalmitis (a serious infection inside the eye) and retinal detachment, which can follow any eye injection, inflammation inside the eye, and a rise in eye pressure within minutes of the injection[1]. Through month 24, the most common side effects in the treated eye, for monthly, every-other-month and sham groups, were eye discomfort (13%, 10% and 11%), wet AMD (12%, 7% and 3%), floaters (10%, 7% and 1%) and bleeding on the white of the eye (8%, 8% and 4%)[1]. Optic ischemic neuropathy, loss of blood flow to the optic nerve, was reported in 1.7% of people treated monthly, 0.2% treated every other month and 0.0% given sham[1]. Deaths occurred in 6.7%, 3.6% and 3.8% of those groups, and the label says the rates and causes were consistent with an elderly population[1].
▸How is Pegcetacoplan (intravitreal) taken?
Each dose is 15mg (0.1mL of a 150mg/mL solution) injected into the vitreous, the clear gel inside the eye, by a qualified physician, once every 25 to 60 days in each affected eye[1]. The injection is done under sterile conditions after numbing and an antiseptic, with a separate vial for each eye. Eye pressure is checked before the injection, and eye pressure and optic nerve blood flow are checked right after it[1]. In the trials, people were treated either monthly or every other month[1]. The label gives no age-based dose change; about 97% of people treated in the trials were 65 or older and about 72% were 75 or older[1]. Safety and effectiveness in children have not been established. For pregnancy, the label says there are no adequate studies and that use may be considered after weighing risks and benefits, since little of the drug reaches the rest of the body after an eye injection[1].
▸Is Pegcetacoplan (intravitreal) FDA approved?
Yes, Pegcetacoplan (intravitreal) (Syfovre) is FDA approved (2023) for the treatment of Geographic Atrophy.
▸How often do you get Syfovre injections?
The label dose is 15mg injected into each affected eye once every 25 to 60 days[1].
In the trials: People were treated either monthly or every other month for 24 months.
Who gives it: A qualified physician, under sterile conditions, with a separate vial for each eye.
Checks: Eye pressure before the injection, and eye pressure and optic nerve blood flow right after.
Source: Syfovre prescribing information, revised July 2025, DailyMed
▸Is Syfovre the same as Empaveli?
They contain the same molecule, pegcetacoplan, but they are separate products with their own FDA labels, doses and uses[1][6].
Syfovre: 15mg injected into the eye every 25 to 60 days for geographic atrophy secondary to AMD, with no boxed warning.
Empaveli: Infused under the skin twice a week, 1,080mg for adults, for PNH, C3 glomerulopathy and primary IC-MPGN, with a boxed warning for serious infections, required vaccines and a REMS safety program.
Why the difference: The Syfovre label says little of the drug reaches the rest of the body after an eye injection.
Source: Syfovre prescribing information, DailyMed; Empaveli prescribing information, DailyMed
▸What is retinal vasculitis with Syfovre?
Retinal vasculitis is inflammation of the blood vessels in the retina, and the Syfovre label warns it can happen, sometimes with a blocked retinal vessel[1].
When: It has been reported after approval, usually with inflammation inside the eye, and can occur with the first dose.
Why it matters: It can cause severe vision loss.
What the label says to do: Stop Syfovre in anyone who develops it, and report any change in vision without delay.
Source: Syfovre prescribing information, revised July 2025, DailyMed
▸What is the difference between Syfovre and Izervay?
Both are complement inhibitors injected into the eye to slow geographic atrophy, and no trial has compared them directly[1][7].
Syfovre (pegcetacoplan, Apellis): Blocks C3, given every 25 to 60 days, approved February 17, 2023.
Izervay (avacincaptad pegol, Astellas): Blocks C5, given once a month, approved August 4, 2023.
Wet AMD by month 24: 12% on monthly Syfovre, 7% every other month and 3% on sham in OAKS and DERBY; 12% on monthly Izervay and 9% on sham in GATHER2.
Other label warnings: Both list eye infection, retinal detachment and raised eye pressure; the Syfovre label also lists retinal vasculitis and inflammation inside the eye.
Caveat: The trials enrolled different people, so their numbers cannot be compared directly.
Sources and references
Every factual claim on this page is drawn from the public sources listed below. Click any reference to open the original document.
- Apellis Pharmaceuticals via DailyMed · 2025-09-19. SYFOVRE (pegcetacoplan injection), for intravitreal use: prescribing information, revised July 2025. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b4434e61-9ec9-4e0e-bd60-45aaa0a87e64
- U.S. Food and Drug Administration. Drugs@FDA: SYFOVRE, NDA 217171, approval history. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=217171
- U.S. Food and Drug Administration · 2023-02-17. NDA 217171 approval letter (Syfovre, pegcetacoplan injection). https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2023/217171Orig1s000ltr.pdf
- ClinicalTrials.gov. A Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (OAKS). https://clinicaltrials.gov/study/NCT03525613
- ClinicalTrials.gov. Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (DERBY). https://clinicaltrials.gov/study/NCT03525600
- U.S. Food and Drug Administration. Drugs@FDA: EMPAVELI, NDA 215014, approval history. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215014
- U.S. National Library of Medicine, DailyMed · 2026-09-03. IZERVAY (avacincaptad pegol intravitreal solution): prescribing information. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1642fe6a-dc26-4d20-ae6e-654af744e3bd
- U.S. Food and Drug Administration · 2023-08-04. NDA 217225 approval letter. https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2023/217225Orig1s000ltr.pdf
- Ophthalmology · 2021. C5 Inhibitor Avacincaptad Pegol for Geographic Atrophy Due to Age-Related Macular Degeneration: A Randomized Pivotal Phase 2/3 Trial. https://doi.org/10.1016/j.ophtha.2020.08.027
- Biogen · 2026-05-14. Biogen Completes Acquisition of Apellis Pharmaceuticals. https://investors.biogen.com/node/30616
- Apellis Pharmaceuticals (Biogen). ApellisAssist. https://syfovre.com/resources-for-you/apellisassist